Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation

NCT02961270 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Icotinib

Sponsor

Chinese Academy of Medical Sciences